We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

AME:NYSEAMETEK, Inc. Analysis

Data as of 2026-03-10 - not real-time

$225.07

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Technical outlook: The short‑term moving average sits above the longer‑term average, indicating a bullish bias, while the RSI hovers in the mid‑40s, suggesting neutral momentum. However, the MACD histogram is negative and the signal line is bearish, warning of potential short‑term weakness. Volume has been trending upward, supporting the current price above recent support levels. Fundamental momentum: The company posted double‑digit revenue growth and margin expansion in its latest quarter, beating expectations and reinforcing its growth narrative.
Valuation and income: The stock trades at a price‑to‑earnings multiple that exceeds the industry average, and a discounted cash‑flow model places fair value well below the market price, flagging a possible overvaluation. Despite this, the dividend yield remains modest with a low payout ratio, indicating a sustainable income stream. The combination of solid earnings, strong cash generation, and a diversified product portfolio supports a positive longer‑term outlook, albeit with caution on price appreciation.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram suggests limited upside
  • Increasing volume provides support for price stability
  • Neutral RSI indicates no clear momentum direction

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Record earnings and double‑digit revenue growth
  • Strong operating and free cash flow generation
  • Sustainable dividend with low payout ratio

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Diversified exposure across aerospace, energy, and medical markets
  • Continued cash flow strength to fund growth initiatives
  • Valuation premium may limit upside but dividend provides steady return

Key Metrics & Analysis

Financial Health

Revenue Growth13.40%
Profit Margin20.00%
P/E Ratio35.2
ROE14.59%
ROA7.88%
Debt/Equity24.19
P/B Ratio4.9
Op. Cash Flow$1.8B
Free Cash Flow$1.3B
Industry P/E29.5

Technical Analysis

TrendBullish
RSI44.8
Support$217.52
Resistance$242.05
MA 20$232.85
MA 50$223.21
MA 200$195.86
MACDBearish
VolumeIncreasing
Fear & Greed Index75.89

Valuation

Fair Value$133.12
Target Price$249.18
Upside/Downside10.71%
GradeOvervalued
TypeGrowth
Dividend Yield0.60%

Risk Assessment

Beta0.82
Volatility23.16%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.